Public Advisory - Recall of one lot of pms-Hydromorphone due to packaging error that could potentially lead to overdose
OTTAWA, ON, Aug. 20, 2022 /CNW/ -
Summary
Product: pms-Hydromorphone, 2 mg tablets (DIN 00885436) marketed by Pharmascience Inc. Sold to pharmacies in bottles of 100 tablets for dispensing to consumers.
Issue: Health product ? product safety
What to do: Check your bottle of pms-Hydromorphone to ensure you have the correct tablets. Stop using product from the affected lot and contact your pharmacy immediately for a replacement product.
Who this is for: General public and pharmacists
Product Image(s):
2 mg: Round, biconvex, orange tablet debossed and half-scored with "2"on one side of the tablet and "pms" on the other side.
8 mg: Round, biconvex, white tablet debossed and half-scored with "8"on one side of the tablet and "pms" on the other side.
Affected products
Product
DIN
Lot
Expiry date
Pharmascience Inc. pms-Hydromorphone 2 mg Hydromorphone Hydrochloride Tablets
Bottles of 100 tablets
00885436
639268
31-01-2026
Issue
Pharmascience Inc. is recalling one lot of pms-Hydromorphone, 2 mg tablets, (lot 639268) as the bottles may contain hydromorphone tablets of a different strength (8 mg), meaning they contain higher amounts of hydromorphone. Products from the affected lot were sold between May 2022 and August 2022.
The 2 mg hydromorphone tablets are round and orange with a "2" on one side of the tablet and "pms" on the other side. The 8 mg hydromorphone tablets are round and white with an "8" on one side of the tablet and "pms" on the other side.
Hydromorphone is an opioid medication used to treat pain and opioid use disorder.
Accidentally taking too much hydromorphone (one dose of 8 mg of hydromorphone instead of one dose of 2 mg) or suddenly increasing the dose of hydromorphone could potentially lead to an overdose, which can be life-threatening even in people who have some tolerance to opioids.
Symptoms of hydromorphone overdose may include: dizziness, drowsiness, confusion, slow heartbeat, slow and difficult breathing, cold and clammy skin, seizure, coma and death.
Patients and their caregivers should be aware of the signs and symptoms of hydromorphone overdose, and should seek medical attention immediately if any of these symptoms are noted. If naloxone is available, be prepared to administer it.
The Department is monitoring the company's recall and will inform the public if any new health risks are identified.
What you should do
Check your bottle of pms-Hydromorphone to ensure you have the correct tablets. The 2 mg hydromorphone tablets are round and orange with a "2" on one side of the tablet and "pms" on the other side. The 8 mg hydromorphone tablets are round and white with an "8" on one side of the tablet and "pms" on the other side.
Stop using product from the affected lot and contact your pharmacy immediately for a replacement product.
If you have accidentally taken the 8 mg hydromorphone tablet instead of the 2 mg hydromorphone tablet and you have any health concerns, or are unsure whether you have taken too much hydromorphone, contact your healthcare professional, hospital emergency department or regional poison control centre immediately, even if there are no symptoms. If naloxone is available, be prepared to administer it.
If you have any questions about the recall, contact Pharmascience Inc. at [email protected] or 1-888-550-6060.
Alert / recall type: Public Advisory Category: Drugs Companies: If you have any questions about the recall, contact Pharmascience Inc. at [email protected] or 1-888-550-6060. Published by: Health Canada
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...
YOUR LEGAL RIGHTS MAY BE AFFECTED
There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...